Comparing secukinumab maintenance schedules for psoriasis
Part of Skin clinical trials.
This study looks at patients with moderate-to-severe psoriasis who have already responded well to secukinumab (an injection that targets the immune system). Researchers want to see which maintenance dosing schedule works best long-term and causes the fewest side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have moderate-to-severe plaque psoriasis (the most common type, with thick, scaly patches)
- You started secukinumab treatment at Nanjing Drum Tower Hospital between January 2020 and December 2025
- You completed the first 5 weeks of treatment and your psoriasis improved significantly (75% better than baseline)
- You have complete medical records from your treatment at this hospital and regular follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This study keeps track of how people with moderate-to-severe psoriasis do over time while using Siliq or other approved treatments. It may help researchers understand how treatments compare in real life.
This trial tests if adding metformin to secukinumab improves psoriasis in overweight or obese patients. If you have moderate-to-severe plaque psoriasis and a BMI of 25 or higher, this study may offer a new treatment option.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This trial tests if sulodexide, a medication that helps blood flow, can keep psoriasis from coming back after you have stopped using a biologic drug (such as strychnicolizumab) because your skin was completely clear for 6 months.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.